New perspectives in optimizing treatment of coronary heart disease and arterial hypertension patients
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Aim. To increase treatment effectiveness in patients with coronary heart disease (CHD) and arterial hypertension (AH).
Material and methods. In total, 104 patients with stable effort angina (SEA) and AH, including 52 subjects receiving combination standard antihypertensive and anti6ischemic therapy, and 52 also receiving trimetazidine, were included in the study. Cardiac patients were examined according to medical standard OST 91500.11.0002-2002. Quality of life (QoL) was assessed with a special questionnaire, «Quality of Life Index Cardiac Version IV».
Results. Increased clinical effectiveness and improved QoL was observed among SEA and AH patients receiving combination therapy including slow6release trimetazidine.
Conclusion. Adding trimetazidine MB to combination therapy of SEA and AH patients improved the quality of pathogenetic treatment.
References
1. Martynov A.I., Ostroumova O.D., Rolik N.L. Arterial'naya gipertenziya u bol'nykh pozhilogo i starcheskogo vozrasta: etiologiya, klinika, diagnostika, lechenie. Klin med 1997; 12: 8-13.
2. Belousov Yu.B., Leonova M.V., Belousov D.Yu. i dr. Osnovy klinicheskoi farmakologii i ratsional'noi terapii: rukovodstvo dlya praktikuyushchikh vrachei. Pod obshch. red. Yu.B. Belousova, M.V. Leonovoi. Moskva «Bionika» 2002; 368 s.
3. Oganov R.G., Glezer M.G., Deev A.D. ot imeni uchastnikov. Rezul'taty Rossiiskogo issledovaniya PARALLEL'': ProgrammA po vyyavleniyu patsientov s neeffektivnoi terapiei β-adrenoblokatorami i sRAvniteL'noi otsenke effektivnosti dobavLEniya k terapii trimetazidina MV ili izosorbida dinitrata pri stabiL''noi stenokardii. Kardiologiya 2007; 3: 4-13.
4. Serdechnaya nedostatochnost'. OST 91500.11.0002-2002. - [Elektr. res.].
5. Eastaugh JL, Calvert MJ, Freemantle N. Highlighting the need for better patient care in stable angina: results of the international Angina Treatment Patterns (ATP) Survey in 7074 patients. Family Practice 2005; 22: 43-50.
6. Hanania G, Haiat R, Olive T, et al. Coronary artery disease observed in general hospitals: ETTIC study. Comparison between trimetazidine and mononitrate isosorbide for patients receiving betablockers. Ann Cardiol Angeiol (Paris) 2002; 51(5): 268-74.
7. Michaelides AP, Spiropoulos K, Dimopoulos K, et al. Antianginal Efficacy of the combination of Trimetazidine-Propranolol Compared with Isosorbide Dinitrate-Propranolol in Patient with Stable Angina. Clin Drug Invest 1997; 13(1): 8-14.
8. The HOPE study investigator. The HOPE (Heart Outcomes Prevention Evaluation) study: the design of a large, simple randomized trial of an angiotensin6converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. J Cardiol 1996; 12: 127-37.
9. The American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) - [Elektr. res.: http://www.aacvpr.org/resources/publications/index.cfm].
10. The Guidelines Advisory Committee (GAC) Recommended Clinical Practice Guidelines - [Elektr. res.: http://www.gacguidelines.ca].
Review
For citations:
Nikolaev N.A. New perspectives in optimizing treatment of coronary heart disease and arterial hypertension patients. Cardiovascular Therapy and Prevention. 2008;7(1):33-38. (In Russ.)
Views:
458
ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)
ISSN 2619-0125 (Online)
Email this article 
